2024 Annual Report
Released
Released
Announcement PDF
HITIQ Limited
ABN 5 6 9 54
ANNUAL
REPORT
30 JUNE 2024
Letter from the Board
Dear Fellow Shareholders,
On behalf of the Board of HITIQ, I am pleased to present HITIQ Limited’s 2024 Annual Report.
Our share price continues to struggle which we as a board find difficult to comprehend considering
there is no company better placed globally to satisfy the ever-growing concussion issues faced by all
sporting codes. This is highlighted by our current diverse client base coving sports such as Australian
Rules Football, Rugby and Soccer amongst others. Our recent compliance with the World Rugby
standards opens the opportunity for global expansion into the Rugby Union market and our ConneQt
product has had significant success in providing concussion management for sport in remote
communities. Beyond our custom mouthguard product we are working diligently with our partners to
ensure we have a retail boil and bite product available for consumers as soon as possible. We also
note the strong Intellectual Property portfolio the company now maintains both in Australia and now
the United States which will continue to make us the world leading in this space.
As a community we are all fully aware that the current standard of care for concussion has been
disjointed and misunderstood. This presents a significant opportunity for HITIQ to standardise the
protocols by better identifying concussion events, providing a best practice assessment and
diagnostic protocol and achieving better return to play and health outcomes for sports participants.
With the significant concerns about CTE and its long-term effects we see the future including
mandated use of technology to identify and record concussive events for all sports participants.
The company remains cashflow negative but the board has implemented strategies that will bring
down administration and other costs but without compromising the long-term strategy which
includes the ability to scale quickly for projected manufacturing growth. Cost cutting has included
reducing the number of board members and head count along with relocating to a premises at more
than 50% cost reduction but with more space for manufacturing. This has resulted in some additional
upfront costs which the company absorbed in FY24.
The company was pleased to welcome a new major shareholder during the year in Harmil Angel
Investments along with new board members Matthew Clayworth and James Barrie. We also take this
opportunity to thank previous board members Otto Buttula, Glenn Smith and Aidan Clarke for their
contribution to the business over the journey. We would also like to thank the management team and
all our employees, for their ongoing personal commitment and contributions to HITIQ.
We look forward to delivering more commercial outcomes in FY25 that will drive additional value for
all stakeholders. HITIQ is best placed to serve the needs of the sporting bodies and the community
across all levels of sport and we strive to make HITIQ the global leader in concussion. I would also
like to thank our many loyal shareholders who continue to support and believe in the Company.
Philip John Carulli
Non-Executive Director on behalf of the Board
HITIQ Limited
Directors' Report
30 June 2024
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'consolidated entity') consisting of HITIQ Limited (referred to hereafter as the 'company' or 'parent entity') and the entities
it controlled at the end of, or during, the year ended 30 June 2024.
Directors
The following persons were directors of HITIQ Limited during the whole of the financial year and up to the date of this report,
unless otherwise stated:
Otto Buttula (resigned 27 November 2023)
Philip Carulli
Matthew Clayworth (appointed 29 November 2023)
Aidan Clarke (resigned 27 November 2023)
Glenn Smith (resigned 23 February 2024)
James Barrie (appointed 23 February 2024)
Michael Vegar (resigned 4 September 2023)
Principal activities
During the financial year the principal continuing activities of the consolidated entity were the development and
commercialisation of concussion management technology.
No significant change in the nature of these activities occurred during the year.
Key risks and uncertainties
HITIQ Limited is subject to both specific as well as general risks.
Sufficiency of funding
The consolidated entity doesn't have a lot of resources and will need more funds to keep working on its technology and
products, and to reach its long-term goals. Furthermore, factors such as how the economy and stock markets are doing are
beyond the control of the directors and may be a hindrance to raise capital.
Technology, manufacturing and product quality risk
The consolidated entity uses different hosting providers to keep its technology platforms and services running smoothly.
However, there's a risk that these systems could go down due to various reasons. If one of the hosting providers stops
working with the company, it could cause problems like lost revenue, damage to the company's reputation, and financial
issues.
Although the Company manufactures its products at its own premises, HITIQ currently relies on a number of external
Suppliers for key components of its technologies. There is no guarantee that these suppliers will be able to meet the cost,
reliability, volume, or lead times required for HITIQ to remain competitive in the future. These suppliers are also exposed to
the regulatory and compliance requirements faced by HITIQ. There is no guarantee that the suppliers will adequately
conform to these standards in the future. A failure to meet regulatory standards could result in enforcement actions that
could be extended to HITIQ.
2
HITIQ Limited
Directors' Report
30 June 2024
Protection of intellectual property
HITIQ’s success depends, in part, on its ability to obtain, maintain and protect its intellectual property, including its patents.
Actions taken by HITIQ to protect its intellectual property may not be adequate, complete or enforceable and may not
prevent the misappropriation of its intellectual property and proprietary information or deter independent development of
similar technologies by others.
HITIQ may also suffer damage if former employees infringe its intellectual property rights or assert their moral rights. The
granting of a patent does not guarantee that HITIQ’s intellectual property is protected and that others will not develop
similar technologies that circumvents such patents.
There can be no assurance that any patents HITIQ owns, controls or licenses, whether now or in the future, will give HITIQ
commercially significant protection of its intellectual property.
Additionally, monitoring unauthorised use of HITIQ’s intellectual property rights is difficult and can be costly. HITIQ may not
be able to detect all unauthorised use of its intellectual property rights.
Changes in laws in Australia and other jurisdictions in which HITIQ operates may adversely affect HITIQ’s intellectual
property rights.
Competition and development of intellectual property
HITIQ is in competition with other companies creating similar technologies. The Company is at risk because its rivals might
gain more customers by being aggressive in sales, marketing, or pricing. There's also a chance HITIQ might not react as
fast as competitors to changes in the market or customer needs. Additionally, new companies entering the industry could
make products that compete with HITIQ's offerings.
Information on directors
The names, qualifications, experience and special responsibilities of each person who has been a director during the year
and to the date of this report are:
Name:
Title:
Experience and expertise:
Michael Vegar
Managing Director and Chief Executive Officer
Mr Vegar is a co-founder and Managing Director of HITIQ.
He has been responsible for creating and executing HITIQ’s strategic plan, fundraising
& developing the product’s vision, as well as growing the HITIQ team from conception
to now a team of 25 people. Mr Vegar has extensive experience in the sporting industry
across a variety of roles with more than 13 years of domain knowledge. He holds a
Bachelor’s Degree of Commerce and a Master’s Degree of Exercise Science.
Before co-founding HITIQ, Mike operated a sport science consultancy firm advising
various professional and semi-professional sporting programs from 2008 – 2017,
including working in the High-Performance Unit at the Australian Institute of Sport with
the Australian Men’s Hockey program. In that role, Mr Vegar was responsible for
managing the injury rehabilitation and physical preparation programming. In 2012, Mr
Vegar also co-founded Game Guardian, a leading Australian manufacturer of mouth
guards and sports protection goods, which he exited in 2020.
Other current directorships:
Former directorships (last 3 years): Interests in shares:
12,437,499
Interests in options:
11,333,333
3
HITIQ Limited
Directors' Report
30 June 2024
Name:
Title:
Experience and expertise:
Otto Buttula
Non-Executive Chair
Mr Buttula has had extensive experience and success in investment research, funds
management and information/biotechnology, holding directorships in a number of
public companies.
Mr Buttula’s executive experience includes as a co-founder, CEO and Managing
Director of IWL Ltd, an online financial services company that listed on the ASX in 1999.
Growing from a market capitalisation of $48 million at listing, it was taken over in 2007
by Commonwealth Bank of Australia (ASX: CBA) for $373 million.
Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which
he was a co-founder and director of Lonsdale Securities Ltd. Following his completion
of executive duties, Mr Buttula was Non-Executive Chairman of platform and
stockbroking provider Investorfirst Ltd and led the acquisition of HUB24 Ltd (ASX:
HUB).
More recently, he served on the Board as a non-executive director and Head of Audit
& Risk at Imugene Ltd (ASX: IMU) between 2014 and 2016. Currently, Mr Buttula is
also Non-Executive Chairman of Rhythm Biosciences Ltd (ASX: RHY), a company
positioning itself to be a global leader in the mass market, early detection of colorectal
cancer, via a simple blood test and a Non-Executive Director of Oncosil Medical Ltd
(ASX: OSL), a commercial brachytherapy provider specialising in pancreatic cancer.
Mr Buttula holds a Bachelor of Economics from Monash University, a Graduate
Diploma of Applied Finance & Investment and is a Fellow of the Australian Institute of
Company Directors.
Other current directorships:
Rhythm Biosciences Limited - appointed 28 October 2019
Former directorships (last 3 years): Oncosil Medical Ltd - appointed 20 July 2021 (retired 31 August 2023)
Interests in shares:
19,778,259
Interests in options:
11,703,866
Name:
Title:
Qualifications:
Philip Carulli
Non-Executive Director
Philip Carulli is a Chartered Accountant and managing director of Optima Financial
Group Pty Ltd where he provides financial, taxation and corporate advisory services to
a diverse range of businesses. Over the past 25 years Mr Carulli has owned, managed
and consulted to companies in professional services, construction, technology,
medical, and industrial sectors to name a few.
He holds a Bachelor of Business and holds a Certificate of Public Practice. Philip has
been working with the company since incorporation in the capacity of financial controller
and former company secretary.
Experience and expertise:
Other current directorships:
Former directorships (last 3 years): Interests in shares:
5,749,566
Interests in options:
3,148,410
4
HITIQ Limited
Directors' Report
30 June 2024
Name:
Title:
Experience and expertise:
Glenn Smith
Non-Executive Director
Glenn Smith is a seasoned “C-level” executive, strategy consultant, and venture
capitalist. Throughout his career, Glenn has excelled in fostering customer-centric
enterprises across various growth phases, spanning both publicly listed and private
companies.
Glenn is also a founding partner and head of the investment committee at Aruma
Capital, an Australian venture capital firm dedicated to funding transformative
technologies that enhance societal well-being. Glenn's educational background
includes an MBA from the University of Western Australia, an Undergraduate Degree
in Arts/Economics, and a Graduate Degree in Viticulture and Oenology.
Other current directorships:
Former directorships (last 3 years): Tali Digital Limited - 10 May 2018 to 31 March 2022
660,000
Interests in shares:
410,000
Interests in options:
Name:
Title:
Experience and expertise:
Aidan Clarke
Non-Executive Director
Mr Clarke is an experienced entrepreneur with close to 15 years’ experience building
and growing global brands within the sporting industry.
Having co-founded sporting brand 2XU, Mr Clarke was an Executive Director
responsible for the Sales & Marketing functions of the company. Equipping multiple
World and Olympic champions in almost every code, whilst building a global distribution
network. 2XU supplied the US Navy Seals, majority of NFL teams, and 29 of the 30
NBA teams. Mr Clarke led 2XU commercialisation efforts into numerous elite sport
relationships, such as a long serving AIS R&D agreement and signing multiple
exclusive partnerships across high performance teams and institutions throughout the
world. 2XU was partially acquired by the LVMH capital arm L-Capital for a $200m
valuation in 2014, with Mr Clarke fully exiting his shareholding in 2018.
Mr Clarke has a BA/Bcomm from Auckland University, and through experience and
track record brings a strong demand generation lens and skillset to HITIQ.
Other current directorships:
Former directorships (last 3 years): 1,012,500
Interests in shares:
881,250
Interests in options:
Name:
Title:
Experience and expertise:
James Barrie
Non-Executive Director & Company Secretary
Mr James Barrie is a professional director and company secretary. He was appointed
HITIQ company secretary on 1 July 2023 and a Non-Executive Director on 23 February
2024. His strength and expertise are driven by his extensive career and background
across various industry sectors, from start-ups to the ASX 20. Mr Barrie provides the
HITIQ Board independent advice and expertise across various governance and
corporate responsibility requirements required of an ASX-listed company. Mr Barrie’s
skills include corporate governance, share registry, employment plans, treasury, capital
management, accounting, commercial analysis, mergers and acquisitions, strategy,
stakeholder relations and business development. He is also the company secretary
and/or a director of several other ASX, NSX or unlisted companies.
Other current directorships:
Boadicea Resources Limited (ASX:BOA) InhaleRX Limited (ASX:IRX) and Phoenician
International Limited (NSX: PHI).
Former directorships (last 3 years): Interests in shares:
140,000
Interests in options:
70,000
5
HITIQ Limited
Directors' Report
30 June 2024
Name:
Title:
Experience and expertise:
Matthew Clayworth
Non-Executive Director
Mr Clayworth is a Senior Investment Advisor with Wilson's Advisory with over 20 years'
experience in Financial Markets. Previous roles include working for Deutsche Bank,
Citi Smith Barney and Morgan Stanley as Vice President in Private Wealth. Matthew
holds a Bachelor of Commerce from the University of Queensland and a Graduate
Diploma in Applied Finance and Investment. He is currently a director of DHD Surf and
a co-founder and director of Smart AI Connect.
Other current directorships:
Former directorships (last 3 years): Interests in shares:
63,653,642
Interests in options:
31,826,822
'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes
directorships of all other types of entities, unless otherwise stated.
Company Secretaries
James Barrie
James Barrie is a professional Director and Company Secretary and provides HIQ with a range of commercially focused
professional services and knowledge, including governance, share registry and employee equity plans, stakeholder relations
support and virtual shareholder meetings.
Mr Barrie (B.Bus, DiplInvRel, CPA, GAICD) is currently company secretary of ASX-listedAccent Resources NL, Global Health
Limited, Jupiter Energy Limited, InhaleRx Limited, and Boadicea Resources Limited, where he is also a Non-Executive
Director. Mr Barrie is also a Non-Executive Director and company secretary of NSX-listed A2A GN Limited and Phoenician
International Limited as well as several unlisted private and pre-IPO companies.
Dividends
There were no dividends paid, recommended or declared during the current or previous financial year.
Review of operations
The loss for the consolidated entity after providing for income tax amounted to $3,204,731 (30 June 2023: $5,037,305).
The Chairman’s Letter and Chief Executive Officer’s Report contain a review of operations.
The major items of expenditure include Research and Testing $635,890 (2023: $854,693), administration costs $1,161,728
(2023: $808,212) and Employee Benefits Expense $4,414,244 (2023: $4,794,485).
Significant changes in the state of affairs
During the year the consolidated entity signed its first commercial deal with National Rugby League (NRL) and the UK Sports
Institute along with re-signing deals with several existing high-quality customers. Additionally, the company has secured new
patents in Australia and Internationally along with meeting the World Rugby Instrumented Mouthguard technology standards
allowing it to make the HITIQ product commercially available in Rugby Union.
A renounceable rights offer was completed in January 2024 raising $2.3 million along with accessing a loan against its R&D
tax incentive of $997k in March 2024 and entering into a Convertible Note with its major shareholder totalling $1.6m in May
2024.
In March 2024 the company entered into a lease for a period of 4 years at White Street in South Melbourne, the terms of
the lease reduce the Group’s rent commitment from its previous premises and also provides additional space for
manufacturing.
6
HITIQ Limited
Directors' report
30 June 2024
Matters subsequent to the end of the financial year
In September 2024 the company has entered into an agreement with existing financier, Keystone Capital Partners, to draw
a further $400,000 loan secured against the expected FY2024 R&D Tax Incentive, the terms of the loan are the same as the
existing facility which is detailed in the financial report.
No further matter or circumstance has arisen since 30 June 2024 that has significantly affected, or may significantly affect
the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future
financial years.
Likely developments and expected results of operations
Information on likely developments in the operations of the consolidated entity and the expected results of operations have
not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the
consolidated entity.
Meetings of directors
The number of meetings of the company's Board of Directors ('the Board') held during the year ended 30 June 2024, and
the number of meetings attended by each director were:
Full Board
Attended
Held
Michael Vegar
Otto Buttula
Philip Carulli
Glenn Smith
Aidan Clarke
Matthew Clayworth
James Barrie
3
5
6
5
5
1
1
3
5
6
5
5
1
1
Held: represents the number of meetings held during the time the director held office.
Shares under option
Unissued ordinary shares of HITIQ Limited under option at the date of this report are as follows:
Grant date
19/03/2021
10/11/2021
22/01/2024
Expiry date
25/03/2025
10/11/2024
31/10/2025
Exercise
price
$0.30
$0.30
$0.05
Number
under option
1,500,000
1,500,000
42,532,854
45,532,854
Shares under option expired during the year
Grant date
23/01/2019
16/03/2020
18/12/2020
19/03/2021
19/03/2021
19/03/2021
22/12/2022
14/07/2021
Expiry date
10/12/2023
17/12/2023
18/12/2023
17/12/2023
19/03/2024
25/03/2024
09/12/2023
31/07/2024
Exercise
price
$0.20
$0.20
$0.30
$0.20
$0.20
$0.30
$0.04
$0.30
Number
under option
3,000,000
1,333,334
2,000,000
599,999
599,999
4,500,000
134,360,271
4,642,250
151,035,853
7
HITIQ Limited
Directors' report
30 June 2024
4,642,250 options expired subsequent to year end.
No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the
company or of any other body corporate.
Shares issued on the exercise of options
There were no ordinary shares of HITIQ Limited issued on the exercise of options during the year ended 30 June 2024 and
up to the date of this report.
Remuneration report (audited)
The remuneration report details the key management personnel remuneration arrangements for the consolidated entity, in
accordance with the requirements of the Corporations Act 2001 and its Regulations.
Key management personnel are those persons having authority and responsibility for planning, directing and controlling the
activities of the entity, directly or indirectly, including all directors.
Key Management Personnel
The following changes are noted to Key Management Personnel for the year ended 30 June 2024:
Except as noted above, the named persons held their current position for the whole of the financial year and since the end
of the financial year.
Executive Directors / CEO
●
Michael Vegar – Managing Director (resigned 4 September 2023)
Non-Executive Directors:
●
Otto Buttula – Non-Executive Chairman (resigned 27 November 2023)
●
Philip Carulli – Non-Executive Director
●
Glenn Smith – Non-Executive Director (resigned 23 February 2024)
●
Aidan Clarke – Non-Executive Director (resigned 27 November 2023)
●
Matthew Clayworth – Non-Executive Director (appointed 29 November 2023)
●
James Barrie – Non-Executive Director (appointed 23 February 2024)
The remuneration report is set out under the following main headings:
●
Principles used to determine the nature and amount of remuneration
●
Details of remuneration
●
Service agreements
●
Share-based compensation
●
Additional information
●
Additional disclosures relating to key management personnel
Principles used to determine the nature and amount of remuneration
The objective of the consolidated entity's executive reward framework is to ensure reward for performance is competitive
and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives
and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of
reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward
governance practices:
●
competitiveness and reasonableness
●
acceptability to shareholders
●
performance linkage / alignment of executive compensation
●
transparency
The Board is responsible for determining and reviewing remuneration arrangements for its directors and executives. The
performance of the entity depends on the quality of its directors and executives. The remuneration philosophy is to attract,
motivate and retain high performance and high-quality personnel. The board has not sought the assistance of a remuneration
consultant during the year.
8
HITIQ Limited
Directors' Report
30 June 2024
The reward framework is designed to align executive reward to shareholders' interests. The Board have considered that it
should seek to enhance shareholders' interests by:
●
having economic profit as a core component of plan design
●
focusing on sustained growth in shareholder wealth, consisting of dividends and growth in share price, and delivering
constant or increasing return on assets as well as focusing the executive on key non-financial drivers of value
●
attracting and retaining high calibre executives
Additionally, the reward framework should seek to enhance executives' interests by:
●
rewarding capability and experience
●
reflecting competitive reward for contribution to growth in shareholder wealth
●
providing a clear structure for earning rewards
In accordance with best practice corporate governance, the structure of non-executive director and executive director
remuneration is separate.
Non-executive directors’ remuneration
Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive directors'
fees and payments are reviewed annually by Board. The Board may, from time to time, receive advice from independent
remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market.
The chairman's fees are determined independently to the fees of other non-executive directors based on comparative roles
in the external market.
ASX listing rules require the aggregate non-executive directors' remuneration be determined periodically by a general
meeting. The remuneration of non-executive directors was set in the Company's Prospectus upon IPO, dated 22 April 2021,
which set a cap of $400,000.
Executive remuneration
The consolidated entity aims to reward executives based on their position and responsibility, with a level and mix of
remuneration which has both fixed and variable components.
The executive remuneration and reward framework has four components:
●
base pay and non-monetary benefits
●
short-term performance incentives
●
share-based payments
●
other remuneration such as superannuation and long service leave
The combination of these comprises the executive's total remuneration.
Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed annually by the
Board based on individual and business unit performance, the overall performance of the consolidated entity and comparable
market remunerations.
Executives may receive their fixed remuneration in the form of cash or other fringe benefits (for example motor vehicle
benefits) where it does not create any additional costs to the consolidated entity and provides additional value to the
executive.
The short-term incentives ('STI') program is designed to align the targets of the business units with the performance hurdles
of executives. STI payments are granted to executives based on specific annual targets and key performance indicators
('KPI's') being achieved. KPI's include profit contribution, customer satisfaction, leadership contribution and product
management.
The long-term incentives ('LTI') include long service leave and share-based payments. Shares are awarded to executives
over a period of three years based on long-term incentive measures. These include increase in shareholders’ value relative
to the entire market and the increase compared to the consolidated entity's direct competitors. The Board reviewed the longterm equity-linked performance incentives specifically for executives during the year ended 30 June 2024.
Consolidated entity performance and link to remuneration
Remuneration for certain individuals are directly linked to the performance of the consolidated entity. Cash bonus and
incentive payments are at the discretion of the Board
9
HITIQ Limited
Directors' Report
30 June 2024
The Board is of the opinion that the continued improved results can be attributed in part to the adoption of performancebased compensation and is satisfied that this improvement will continue to increase shareholder wealth if maintained over
the coming years.
Voting and comments made at the company's 29 November 2023 Annual General Meeting ('AGM')
At the 29 November 2023 AGM, 82.90% of the votes received supported the adoption of the remuneration report for the year
ended 30 June 2023. The company did not receive any specific feedback at the AGM regarding its remuneration practices.
Details of remuneration
Amounts of remuneration
Details of the remuneration of key management personnel of the consolidated entity are set out in the following tables.
Short-term benefits
Cash salary
and fees
$
2024
Executive Director/CEO::
Michael Vegar
Non-Executive Directors:
Otto Buttula
Philip Carulli
Glenn Smith
Aidan Clarke
Matthew Clayworth
James Barrie (ii)
Cash
bonus
$
Non-Executive Directors:
Otto Buttula
Philip Carulli
Glenn Smith
Aidan Clarke
(i)
(ii)
Long
service
leave
$
Equitysettled (i)
$
Superannuation
$
Total
$
210,000
-
12,170
23,100
4,036
-
249,306
35,538
42,000
89,645
14,000
24,500
51,770
467,453
-
12,170
3,910
27,010
4,036
-
39,448
42,000
89,645
14,000
24,500
51,770
510,669
Cash salary
and fees
$
Executive Director:
Michael Vegar
Sharebased
payments
Nonmonetary
$
Short-term benefits
2023
Postemployment Long-term
benefits
benefits
Cash
bonus
$
-
Postemployment Long-term
benefits
benefits
Sharebased
payments
Long
service
leave
$
Equitysettled (i)
$
Total
$
Nonmonetary
$
Superannuation
$
210,000
-
20,244
22,050
24,982
(329,794)
(52,518)
84,000
42,000
42,000
42,000
420,000
-
19,257
39,501
8,820
30,870
1,939
26,921
(16,763)
(8,381)
(8,381)
(8,381)
(371,700)
97,253
33,619
33,619
33,619
145,592
Equity settled remuneration for FY23 relates to the vesting of share-based payment arrangements issued in prior
years. Several tranches of share-based payment arrangements had non-market hurdles attached, which were
reassessed by the Board of Directors and determined that these would not be met resulting in the reversal of previous
amounts expensed in relation to these, and the negative charge in the remuneration report.
Includes Non-Executive fees and those for Company Secretary services
10
HITIQ Limited
Directors' Report
30 June 2024
The proportion of remuneration linked to performance and the fixed proportion are as follows:
Name
Fixed remuneration
2024
2023
At risk - STI
2024
2023
At risk - LTI
2024
2023
Executive Directors:
Mi
Share your feedback
Discover